Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Davidson

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Haematologica|March 9, 2019
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based studyVincent Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
Annals of Internal Medicine|October 16, 2002
Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trialCharles W Francis, Bruce L Davidson, Scott D Berkowitz, et al.
Annals of Internal Medicine|June 3, 2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialHarry R Büller, Bruce L Davidson, Hervé Decousus, et al.
Thrombosis Journal|September 24, 2013
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesMartin H Prins, Anthonie Wa Lensing, Rupert Bauersachs, et al.
Thrombosis Research|November 29, 2020
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic eraWei Qin, Fen Dong, Zhu Zhang, et al.
Lancet (London, England)|May 5, 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie, Michael R Lassen, Bruce L Davidson, et al.
Journal of the American College of Cardiology|April 4, 2015
Practical management of anticoagulation in patients with atrial fibrillationRichard J Kovacs, Greg C Flaker, Sherry J Saxonhouse, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
The Journal of Arthroplasty|June 7, 2008
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, Jeffrey S Ginsberg, Bruce L Davidson, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Haematologica|March 9, 2019
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based studyVincent Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
Annals of Internal Medicine|October 16, 2002
Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trialCharles W Francis, Bruce L Davidson, Scott D Berkowitz, et al.
Annals of Internal Medicine|June 3, 2004
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialHarry R Büller, Bruce L Davidson, Hervé Decousus, et al.
Thrombosis Journal|September 24, 2013
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesMartin H Prins, Anthonie Wa Lensing, Rupert Bauersachs, et al.
Thrombosis Research|November 29, 2020
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic eraWei Qin, Fen Dong, Zhu Zhang, et al.
Lancet (London, England)|May 5, 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie, Michael R Lassen, Bruce L Davidson, et al.
Journal of the American College of Cardiology|April 4, 2015
Practical management of anticoagulation in patients with atrial fibrillationRichard J Kovacs, Greg C Flaker, Sherry J Saxonhouse, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
The Journal of Arthroplasty|June 7, 2008
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, Jeffrey S Ginsberg, Bruce L Davidson, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
Pageof 8